Dr Ivy Ho is Principal Investigator and Head of the Molecular Neurotherapeutics Laboratory at the National Neuroscience Institute. She obtained her Ph.D. from the National University of Singapore, specialising in viral gene therapy for glioma treatment.

Dr Ho's research programme centres on elucidating the intrinsic and microenvironmental determinants that modulate glioma therapeutic efficacy. Her laboratory investigates the reciprocal signalling mechanisms between glioma cells and the immune microenvironment, with particular emphasis on how these interactions influence tumour invasion and mesenchymal transition processes.Current research initiatives focus on developing extracellular vesicle platforms for targeted gene delivery applications. Additionally, her laboratory examines extracellular vesicles within the context of the neuroimmune axis, investigating extrinsic communication pathways between tumour cells and immune cell populations. This work encompasses the characterisation of neuroinflammatory processes and their consequential effects on tumour progression and therapeutic resistance.

Dr Ho's translational research approach integrates molecular mechanisms with therapeutic development, contributing to the advancement of precision medicine strategies for malignant glioma treatment. Her work addresses critical gaps in understanding tumour-immune interactions that may inform novel therapeutic interventions for these challenging central nervous system malignancies.

• Ph.D., National University of Singapore, 2005
• M.Sc. University of Leicester, UK 1996
• B.Sc. University of Arizona, USA, 1994

• Principal Investigator, National Neuroscience Institute
• Assistant Professor, Duke-NUS Medical School
• Adjunct Assistant Professor, National University of Singapore
• Subject Expert, SingHealth Institutional Biosafety Committee

• Brain tumor biology
• Neuroinflammation
• Extracellular vesicles
• Tumor microenvironment
• NF1

• M HP, Siew RWE, Aw AYY, Tan JHY, Muhammad YSM, Tye JSN, Prasad K, Kuhle J, Chao YX, Ho IAW, Yeo TR. Longitudinal quantification of serum SARS-CoV2 neutralizing antibodies, proinflammatory cytokines, NFL and GFAP before and after breakthrough COVID-19 infection in CNS neuroimmunological diseases. (2025). Ther Adv Infect Dis 2025, Vol. 12: 1–16
• Vijayanathan Y, Ho IAW. The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies. (2025) Int J Mol Sci 26(2):669. doi; 10.339/ijms26020669. PMID: 39859381
• Scheer M, Leisz S, Sorge E, Storozhuk O, Prell J, Ho I, Harder A. (2022). Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas. Int J Mol Sci 23 (1): 253. doi: 10.3390/ijms23010352. PMID: 35008787
• Ho RLY, Ho IA. (2021). Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade. Cancers, 13(15), 3686; https://doi.org/10.3390/cancers13153686. PMID: 34359588
• Fadhullah SF, Abdul Halim N, Yeo JYT, Ho RLY, Um P, Ang BT, Tang C, Ng WH, Virshup DM, Ho IA. (2019). Pathogenic mutations in neurofibromin identifies a leucine rich domain regulating glioma cell invasiveness. Oncogene 38(27):5367-5380. PMID: 30967630
• For Full List of Publications: ‪Ivy AW Ho-‪Google Scholar